• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

人月经血源性干细胞在COVID-19中的免疫调节治疗：一例病例报告及文献综述

Human menstrual blood-derived stem cells as immunoregulatory therapy in COVID-19: A case report and review of the literature.

作者信息

Lu Juan, Xie Zhong-Yang, Zhu Dan-Hua, Li Lan-Juan

机构信息

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China.

出版信息

World J Clin Cases. 2021 Mar 6;9(7):1705-1713. doi: 10.12998/wjcc.v9.i7.1705.

DOI:10.12998/wjcc.v9.i7.1705
PMID:33728315
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7942055/
Abstract

BACKGROUND

The coronavirus disease 2019 (COVID-19) caused by novel coronavirus 2019 in December 2019 has spread all around the globe and has caused a pandemic. There is still no current effective guidance on the clinical management of COVID-19. Mesenchymal stem cell therapy has been shown to be one of the therapeutic approaches to alleviate pneumonia and symptoms through their immunomo-dulatory effect in COVID-19 patients.

CASE SUMMARY

We describe the first confirmed case of COVID-19 in Hangzhou to explore the role of human menstrual blood-derived stem cells (MenSCs) in the treatment of COVID-19. Moreover, we review the immunomodulation effect including non-specific and specific immune functions of MenSCs for the therapy of COVID-19.

CONCLUSION

MenSCs can be helpful to find a promising therapeutic approach for COVID-19.

摘要

背景

2019年12月新型冠状病毒引发的2019冠状病毒病（COVID-19）已在全球范围内传播并引发了大流行。目前对于COVID-19的临床管理仍没有有效的指导。间充质干细胞疗法已被证明是通过其对COVID-19患者的免疫调节作用来缓解肺炎和症状的治疗方法之一。

病例摘要

我们描述了杭州首例确诊的COVID-19病例，以探讨人月经血来源干细胞（MenSCs）在治疗COVID-19中的作用。此外，我们回顾了MenSCs的免疫调节作用，包括其对COVID-19治疗的非特异性和特异性免疫功能。

结论

MenSCs有助于为COVID-19找到一种有前景的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11ee/7942055/bff7b62092fc/WJCC-9-1705-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11ee/7942055/bff7b62092fc/WJCC-9-1705-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11ee/7942055/bff7b62092fc/WJCC-9-1705-g001.jpg

相似文献

1
Human menstrual blood-derived stem cells as immunoregulatory therapy in COVID-19: A case report and review of the literature.人月经血源性干细胞在COVID-19中的免疫调节治疗：一例病例报告及文献综述
World J Clin Cases. 2021 Mar 6;9(7):1705-1713. doi: 10.12998/wjcc.v9.i7.1705.
2
Immunomodulation and Regeneration Properties of Dental Pulp Stem Cells: A Potential Therapy to Treat Coronavirus Disease 2019.牙髓干细胞的免疫调节和再生特性：一种治疗 2019 年冠状病毒病的潜在疗法。
Cell Transplant. 2020 Jan-Dec;29:963689720952089. doi: 10.1177/0963689720952089.
3
Menstrual blood-derived stromal stem cells inhibit optimal generation and maturation of human monocyte-derived dendritic cells.月经血源性基质干细胞抑制人单核细胞衍生树突状细胞的最佳生成和成熟。
Immunol Lett. 2014 Dec;162(2 Pt B):239-46. doi: 10.1016/j.imlet.2014.10.005. Epub 2014 Oct 18.
4
Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment.间充质干细胞及其衍生的外泌体对 COVID-19 治疗的免疫调节作用。
BMB Rep. 2020 Aug;53(8):400-412. doi: 10.5483/BMBRep.2020.53.8.121.
5
[Mesenchymal stem cells in the treatment of COVID-19-progress and challenges].[间充质干细胞治疗COVID-19的进展与挑战]
Sheng Wu Gong Cheng Xue Bao. 2020 Oct 25;36(10):1970-1978. doi: 10.13345/j.cjb.200216.
6
Human Menstrual Blood-Derived Stem Cells Ameliorate Liver Fibrosis in Mice by Targeting Hepatic Stellate Cells via Paracrine Mediators.人月经血源性干细胞通过旁分泌介质靶向肝星状细胞减轻小鼠肝纤维化。
Stem Cells Transl Med. 2017 Jan;6(1):272-284. doi: 10.5966/sctm.2015-0265. Epub 2016 Jul 28.
7
Transplantation of Human Menstrual Blood-Derived Mesenchymal Stem Cells Alleviates Alzheimer's Disease-Like Pathology in APP/PS1 Transgenic Mice.人月经血源性间充质干细胞移植减轻APP/PS1转基因小鼠的阿尔茨海默病样病理变化
Front Mol Neurosci. 2018 Apr 24;11:140. doi: 10.3389/fnmol.2018.00140. eCollection 2018.
8
Menstrual blood-derived stem cells: toward therapeutic mechanisms, novel strategies, and future perspectives in the treatment of diseases.经血来源的干细胞：治疗疾病的治疗机制、新策略和未来展望。
Stem Cell Res Ther. 2019 Dec 21;10(1):406. doi: 10.1186/s13287-019-1503-7.
9
[Mesenchymal stem cells in therapy of coronavirus disease 2019 - a review].[间充质干细胞在2019冠状病毒病治疗中的应用——综述]
Sheng Wu Gong Cheng Xue Bao. 2020 Oct 25;36(10):1979-1991. doi: 10.13345/j.cjb.200355.
10
Human menstrual blood-derived stem cells promote functional recovery in a rat spinal cord hemisection model.人月经血来源的干细胞促进大鼠脊髓半切模型的功能恢复。
Cell Death Dis. 2018 Aug 29;9(9):882. doi: 10.1038/s41419-018-0847-8.

引用本文的文献

1
Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis.MSC 细胞疗法治疗 COVID-19 住院患者的疗效和安全性：系统评价和荟萃分析。
Stem Cells Transl Med. 2022 Jul 20;11(7):688-703. doi: 10.1093/stcltm/szac032.
2
Non-gynaecological Applications of Menstrual-derived Stem Cells: A Systematic Review.月经来源干细胞的非妇科应用：一项系统综述
Avicenna J Med Biotechnol. 2022 Jan-Mar;14(1):10-29. doi: 10.18502/ajmb.v14i1.8166.
3
Stem cell-based therapy for COVID-19 and ARDS: a systematic review.

本文引用的文献

1
Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19.抗2019冠状病毒病的药物重新利用、现有疫苗及新治疗方法研发计划
Front Pharmacol. 2020 Aug 19;11:1258. doi: 10.3389/fphar.2020.01258. eCollection 2020.
2
Mesenchymal stem cells and exosome therapy for COVID-19: current status and future perspective.间充质干细胞和外泌体治疗 COVID-19：现状和未来展望。
Hum Cell. 2020 Oct;33(4):907-918. doi: 10.1007/s13577-020-00407-w. Epub 2020 Aug 11.
3
Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19.
基于干细胞的新冠肺炎和急性呼吸窘迫综合征治疗：一项系统综述。
NPJ Regen Med. 2021 Nov 8;6(1):73. doi: 10.1038/s41536-021-00181-9.
4
Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment.间充质基质细胞：COVID-19治疗的潜在选择。
Pharmaceutics. 2021 Sep 16;13(9):1481. doi: 10.3390/pharmaceutics13091481.
临床研究使用间充质干细胞治疗重症 COVID-19 患者。
Front Med. 2020 Oct;14(5):664-673. doi: 10.1007/s11684-020-0810-9. Epub 2020 Aug 6.
4
The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflame-aging".COVID-19 感染老年患者细胞因子风暴的可能病理生理学机制：“炎症性衰老”的作用。
Inflamm Res. 2020 Sep;69(9):825-839. doi: 10.1007/s00011-020-01372-8. Epub 2020 Jun 11.
5
Clinical features of familial clustering in patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉 2019 年新型冠状病毒感染患者家族聚集性的临床特征。
Virus Res. 2020 Sep;286:198043. doi: 10.1016/j.virusres.2020.198043. Epub 2020 Jun 2.
6
Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More.瑞德西韦治疗 COVID-19 的可能分子机制：需要了解更多。
Arch Med Res. 2020 Aug;51(6):585-586. doi: 10.1016/j.arcmed.2020.05.001. Epub 2020 May 12.
7
Mesenchymal stem cells as a potential therapy for COVID-19.间充质干细胞作为 COVID-19 的一种潜在疗法。
Stem Cell Res Ther. 2020 May 4;11(1):169. doi: 10.1186/s13287-020-01678-8.
8
Cytokine storm intervention in the early stages of COVID-19 pneumonia.COVID-19 肺炎早期的细胞因子风暴干预。
Cytokine Growth Factor Rev. 2020 Jun;53:38-42. doi: 10.1016/j.cytogfr.2020.04.002. Epub 2020 Apr 25.
9
SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options.严重急性呼吸综合征冠状病毒 2 引起的肺炎相关呼吸障碍（COVID-19）：诊断和拟议治疗选择。
Eur Rev Med Pharmacol Sci. 2020 Apr;24(7):4016-4026. doi: 10.26355/eurrev_202004_20871.
10
Transplantation of ACE2 Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia.血管紧张素转换酶2间充质干细胞移植改善新型冠状病毒肺炎患者的预后。
Aging Dis. 2020 Mar 9;11(2):216-228. doi: 10.14336/AD.2020.0228. eCollection 2020 Apr.